New skin treatment shows promise for eczema relief
NCT ID NCT06585202
Summary
This study tested an experimental drug called ATI-2138 in 14 adults with moderate to severe atopic dermatitis (eczema) for 12 weeks. Researchers wanted to see if the drug was safe and if it could reduce skin inflammation and itching. The study measured changes in skin severity, itch intensity, and how much of the body was affected by eczema.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Aclaris Investigational Site
Birmingham, Alabama, 35244, United States
-
Aclaris Investigational Site
Encino, California, 91436, United States
-
Aclaris Investigational Site
San Diego, California, 92123, United States
-
Aclaris Investigational Site
Plainfield, Indiana, 46168, United States
-
Aclaris Investigational Site
Austin, Texas, 78759, United States
-
Aclaris Investigational Site
San Antonio, Texas, 78213, United States
Conditions
Explore the condition pages connected to this study.